04:40 AM EDT, 06/16/2025 (MT Newswires) -- QIAGEN ( QGEN ) and Incyte ( INCY ) said Sunday that they have collaborated to develop a next-generation sequencing diagnostic panel to support Incyte's ( INCY ) portfolio of investigational therapies for myeloproliferative neoplasms, a group of rare blood cancers.

The companies said the therapies include INCA033989, Incyte's ( INCY ) monoclonal antibody targeting mutant calreticulin, which is currently in development for myelofibrosis and essential thrombocythemia.

Under the agreement, the companies said QIAGEN ( QGEN ) will design a multimodal next-generation sequencing panel to detect key gene alterations relevant to hematologic malignancies.

The panel will be validated using the Illumina (ILMN) NextSeq 550Dx platform, the companies said.

They added that QIAGEN ( QGEN ) will also support regulatory submissions and market access strategies in the United States, the European Union, and the Asia-Pacific, helping to advance companion diagnostic tools that align with Incyte's ( INCY ) targeted therapies.